The future of immunisation policy, implementation, and financing

The Lancet

Volumn 378, Issue 9789, 2011, Pages 439-448

  Levine, Orin S ^a   Bloom, David E ^b   Cherian, Thomas ^c   De Quadros, Ciro ^d   Sow, Samba ^e   Wecker, John ^f   Duclos, Philippe ^c   Greenwood, Brian ^g  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Albert B Sabin Vaccine Institute   (United States)

^e Center for Vaccine Development   (Mali)

^f PATH   (United States)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE;

EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; LOWEST INCOME GROUP; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SMALLPOX; WORLD HEALTH ORGANIZATION;

EID: 79960897597     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60406-6     Document Type: Review

References (41)

1. Watt JP, Wolfson LJ, O'Brien KL, et al, and for the Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374: 903-11.
2. O'Brien KL, Wolfson LJ, Watt JP, et al, and for the Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
3. Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200 (suppl 1): S9-15.
4. Brenzel L, Wolfson LJ, Fox-Rushby J, Miller MA, Halsey NA. Vaccine preventable diseases. In: Jamison DT, Breman JG, Measham AR, et al, eds. Disease control priorities in developing countries, 2nd edn. New York, NY: Oxford University Press, 2006: 389-412.
5. Centers for Disease Control and Prevention. Global routine vaccination coverage, 2009. MMWR Morb Mortal Wkly Rep 2010; 59: 1367-71.
6. Loevinsohn B, Aylward B, Steinglass R, Ogden E, Goodman T, Melgaard B. Impact of targeted programs on health systems: a case study of the polio eradication initiative. Am J Public Health 2002; 92: 19-23. (Pubitemid 36018879)
7. WHO. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009: conclusions and recommendations. Wkly Epidemiol Rec 2009; 84: 517-32.
8. Bill & Melinda Gates Foundation. Global health leaders launch Decade of Vaccines collaboration. Dec 2, 2010. http://www.gatesfoundation.org/press- releases/Pages/decade-of-vaccines-collaboration.aspx (accessed March 31, 2011).
9. Bilous J, Eggers R, Gasse F, et al. A new global immunisation vision and strategy. Lancet 2006; 367: 1464-66.
10. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-26. (Pubitemid 351632017)
11. Bryson M, Duclos P, Jolly A, Cakmak N. A global look at national Immunization Technical Advisory Groups. Vaccine 2010; 28 (suppl 1): A13-17.
12. Senouci K, Blau J, Nyambat B, et al. The Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) initiative: a country-driven, multi-partner program to support evidence-based decision making. Vaccine 2010; 28 (suppl 1): A26-30.
13. Cohen D, Carter P. WHO and the pandemic flu "conspiracies". BMJ 2010; 340: c2912.
14. Levine OS, Knoll MD, Jones A, Walker DG, Risko N, Gilani Z. Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions. Curr Opin Infect Dis 2010; 23: 236-41.
15. Wenger JD, DiFabio J, Landaverde JM, Levine OS, Gaafar T. Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries. Vaccine 1999; 18: 736-42. (Pubitemid 29509859)
16. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003; 143 (6 suppl): S163-87. (Pubitemid 37510629)
17. Shearer JC, Stack ML, Richmond MR, Bear AP, Hajjeh RA, Bishai DM. Accelerating policy decisions to adopt Haemophilus influenzae type B vaccine: a global, multivariable analysis. PLoS Med 2010; 7: e1000249.
18. Levine OS, Cherian T, Shah R, Batson A. PneumoADIP: an example of translational research to accelerate pneumococcal vaccination in developing countries. J Health Popul Nutr 2004; 22: 268-74. (Pubitemid 39585860)
19. Wecker JR, Phillips DC, Hayes J. Rotavirus vaccines: the role of researchers in moving evidence to action. Vaccine 2009; 27 (suppl 5): F4-6.
20. Hajjeh RA, Privor-Dumm L, Edmond K, et al. Supporting new vaccine introduction decisions: lessons learned from the Hib initiative experience. Vaccine 2010; 28: 7123-29.
21. Levine OS, Hajjeh R, Wecker J, et al. A policy framework for accelerating adoption of new vaccines. Hum Vaccin 2010; 6: 1021-24.
22. Clemens J, Holmgren J, Kaufmann SH, Mantovani A. Ten years of the Global Alliance for Vaccines and Immunization: challenges and progress. Nat Immunol 2010; 11: 1069-72.
23. WHO. Revolutionary new meningitis vaccine set to wipe out deadly epidemics in Africa. Dec 6, 2010. http://www.who.int/mediacentre/news/releases/ 2010/meningitis-20101206/en/index.html (accessed March 30, 2011).
24. Knoll MD, Moisi JC, Muhib FB, et al. Standardizing surveillance of pneumococcal disease. Clin Infect Dis 2009; 48 (suppl 2): S37-48.
25. Widdowson MA, Steele D, Vojdani J, Wecker J, Parashar U. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J Infect Dis 2009; 200 (suppl 1): S1-8.
26. WHO. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol Rec 2010; 85: 434-36.
27. Scott JA, English M. What are the implications for childhood pneumonia of successfully introducing Hib and pneumococcal vaccines in developing countries? PLoS Med 2008; 5: e86.
28. Bines JE, Patel M, Parashar U. Assessment of postlicensure safety of rotavirus vaccines, with emphasis on intussusception. J Infect Dis 2009; 200 (suppl 1): S282-90.
29. Bloom DE, Canning D, Weston M. The value of vaccination. World Econ 2005; 6: 15-39.
30. Bärnighausen T, Bloom DE, Canning D, O'Brien J. Accounting for the full benefits of childhood vaccination in South Africa. S Afr Med J 2008; 98: 842-46.
31. Bärnighausen T, Bloom DE, Canning D, et al. Best practice paper: the economic case for expanding vaccination coverage of children. 2009. http://www.copenhagenconsensus.com/Default.aspx?ID=1308 (accessed March 30, 2011).
32. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moisi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med 2009; 7: 47.
33. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 317-28.
34. Edmond K, Dieye Y, Griffiths UK, et al. Prospective cohort study of disabling sequelae and quality of life in children with bacterial meningitis in urban Senegal. Pediatr Infect Dis J 2010; 29: 1023-29.
35. International AIDS Vaccine Initiative. Procurement and pricing of new vaccines for developing countries. August, 2008. http://www.iavi.org/ publications-resources/pages/PublicationDetail.aspx?pubID=af228b16-948c-4ca0- bfeb-caf2f6122055 (accessed April 7, 2011).
36. Centers for Disease Control and Prevention. CDC vaccine price list. http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm (accessed March 20, 2011).
37. UNICEF. Product menu for vaccines supplied by the UNICEF for the GAVI alliance. May 31, 2010. http://www.unicef.org/supply/files/Product-Menu-update- 31-May.pdf (accessed April 7, 2011).
38. Pan American Health Organization. PAHO revolving fund: vaccine and syringe prices, 2010. February, 2010. http://www.paho.org/english/ad/fch/im/ sne3201.pdf (accessed April 4, 2011).
39. Lee GM, Santoli JM, Hannan C, et al. Gaps in vaccine financing for underinsured children in the United States. JAMA 2007; 298: 638-43. (Pubitemid 47236415)
40. Lindley MC, Shen AK, Orenstein WA, Rodewald LE, Birkhead GS. Financing the delivery of vaccines to children and adolescents: challenges to the current system. Pediatrics 2009; 124 (suppl 5): S548-57.
41. Moxon ER, Siegrist C-A. The next decade of vaccines: societal and scientific challenges. Lancet 2011; published online June 9. DOI:10.1016/S0140-6736(11)60407-8.